Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab Mode of Action in Chronic Idiopathic Urticaria
NCT01599637Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in chronic idiopathic urticaria (CIU), sponsored by Novartis. Started Apr 2012; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT01599637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01599637.